---
layout: default
title: Desflurane
parent: 僅模型預測 (L5)
nav_order: 227
evidence_level: L5
indication_count: 10
---

# Desflurane
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Desflurane: From General Anesthesia to Nephrogenic Syndrome of Inappropriate Antidiuresis

## One-Sentence Summary

Desflurane is a volatile halogenated inhalational anesthetic used for induction and maintenance of general anesthesia in surgical settings.
The TxGNN model predicts it may be effective for **Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD)**,
with **no clinical trials** and **no publications** currently supporting this direction — the prediction rests entirely on knowledge graph inference.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | General anesthesia (induction and maintenance) |
| Predicted New Indication | Nephrogenic Syndrome of Inappropriate Antidiuresis |
| TxGNN Prediction Score | 98.90% |
| Evidence Level | L5 |
| Singapore Market Status | ✗ Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information, Desflurane is a volatile fluorinated ether used as an inhaled general anesthetic; its clinical efficacy for surgical anesthesia has been well established. The mechanism underlying its anesthetic effect involves potentiation of inhibitory GABA-A receptors and inhibition of excitatory NMDA receptors, leading to global CNS depression.

Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD) is a rare X-linked condition caused by gain-of-function mutations in the V2 vasopressin receptor (AVPR2), resulting in constitutive receptor activation, inappropriate water reabsorption, and dilutional hyponatremia — independent of circulating ADH levels. The standard management approach focuses on fluid restriction and, in some cases, V2 receptor antagonists (vaptans).

The theoretical link between Desflurane and NSIAD is speculative. Volatile anesthetics are known to transiently modulate renal tubular function and may influence ADH-independent water transport pathways. However, NSIAD's pathology is driven by a constitutively active receptor mutation, and no evidence suggests that Desflurane can specifically antagonise or modulate V2 receptor gain-of-function. The practical barrier of inhalational delivery for a chronic renal condition further limits translational plausibility. This prediction most likely reflects indirect network proximity in the TxGNN knowledge graph rather than a direct biological relationship.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Singapore Market Information

Desflurane currently holds **no product registrations** with the Health Sciences Authority (HSA) of Singapore and is not marketed in Singapore.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note:** TFDA package insert warnings, contraindications, and drug interaction data were not available at the time of this report (Data Gaps DG001, DG002). Before any further evaluation, these data must be retrieved from the regulatory authority's official monograph.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN model assigns a high numerical score (98.90%) to this indication, but this score reflects rank within the model's output distribution rather than clinical confidence; the actual knowledge graph rank is 11,286, indicating numerous other indications were predicted more strongly for other drugs. There is zero clinical trial evidence, zero peer-reviewed literature support, no biologically established mechanism linking Desflurane to NSIAD pathophysiology, and Desflurane is not marketed in Singapore — collectively, this candidate does not meet the threshold for further investment at this time.

**To proceed, the following is needed:**
- Retrieve TFDA / HSA-equivalent package insert to document approved indications, warnings, and contraindications (resolves DG001)
- Obtain confirmed mechanism of action data from DrugBank API (resolves DG002)
- Conduct a targeted literature search to determine whether any in vitro or animal model data supports an interaction between volatile anesthetics and V2 receptor or aquaporin-2 (AQP2) pathways
- Evaluate whether the route of administration (inhalational) is fundamentally incompatible with treating a chronic rare renal disorder; if incompatible, archive the candidate without further investigation
- If mechanistic evidence is found, design a feasibility assessment for alternative delivery or prodrug formulation before committing to preclinical studies

---

*⚠️ Disclaimer: This report is for research reference purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

